Literature DB >> 28131709

Design, synthesis and evaluation of novel bifunctional tetrahydroxamate chelators for PET imaging of 89Zr-labeled antibodies.

Julie Rousseau1, Zhengxing Zhang1, Gemma M Dias1, Chengcheng Zhang1, Nadine Colpo1, François Bénard2, Kuo-Shyan Lin3.   

Abstract

Two compact and symmetrical bifunctional tetrahydroxamate chelators, 1 and 2, were synthesized and evaluated for labeling antibodies with 89Zr for imaging with positron emission tomography. Using 2,2'-iminodiacetamide as the backbone, four hydroxamate-containing moieties coupled to the diacetamide nitrogen were used for 89Zr labeling, while a pendant connected to the amino group provided an isothiocyanate group for coupling to the antibody. Both 1- and 2-conjugated Trastuzumab were labeled with 89Zr efficiently (>90% radiolabeling yield), and their 89Zr-labeled products maintained comparable immunoreactivity to Trastuzumab. Compared to 89Zr-labeled deferoxamine-conjugated Trastuzumab, 89Zr-1- and 89Zr-2-Trastuzumab showed faster demetalation in mouse plasma, and also displayed higher bone uptake in mice. Despite suboptimal stability of 89Zr complexes of 1 and 2, our design strategy led to tetrahydroxamate chelators for efficient 89Zr labeling, and could be potentially modified to provide novel chelators with improved stability.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody; Bifunctional chelators; Molecular imaging; Positron emission tomography; Trastuzumab; Zirconium-89

Mesh:

Substances:

Year:  2017        PMID: 28131709     DOI: 10.1016/j.bmcl.2017.01.052

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents.

Authors:  Nikunj B Bhatt; Darpan N Pandya; Stephanie Rideout-Danner; Howard D Gage; Frank C Marini; Thaddeus J Wadas
Journal:  Dalton Trans       Date:  2018-09-04       Impact factor: 4.390

2.  Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO.

Authors:  N V S Dinesh K Bhupathiraju; Ali Younes; Minhua Cao; Jafar Ali; Huseyin T Cicek; Kathryn M Tully; Shashikanth Ponnala; John W Babich; Melissa A Deri; Jason S Lewis; Lynn C Francesconi; Charles Michael Drain
Journal:  Org Biomol Chem       Date:  2019-07-17       Impact factor: 3.876

Review 3.  Current Perspectives on 89Zr-PET Imaging.

Authors:  Joon-Kee Yoon; Bok-Nam Park; Eun-Kyoung Ryu; Young-Sil An; Su-Jin Lee
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

4.  Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89.

Authors:  Chuangyan Zhai; Shanzhen He; Yunjie Ye; Christine Rangger; Piriya Kaeopookum; Dominik Summer; Hubertus Haas; Leopold Kremser; Herbert Lindner; Julie Foster; Jane Sosabowski; Clemens Decristoforo
Journal:  Biomolecules       Date:  2019-03-06

5.  Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET.

Authors:  Marion Chomet; Maxime Schreurs; Maria J Bolijn; Mariska Verlaan; Wissam Beaino; Kari Brown; Alex J Poot; Albert D Windhorst; Herman Gill; Jan Marik; Simon Williams; Joseph Cowell; Gilles Gasser; Thomas L Mindt; Guus A M S van Dongen; Danielle J Vugts
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-05       Impact factor: 9.236

6.  Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression.

Authors:  Dominik Summer; Javad Garousi; Maryam Oroujeni; Bogdan Mitran; Ken G Andersson; Anzhelika Vorobyeva; John Löfblom; Anna Orlova; Vladimir Tolmachev; Clemens Decristoforo
Journal:  Mol Pharm       Date:  2017-12-01       Impact factor: 4.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.